ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action
R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
FDA AMDAC – Developing Single-Pathogen agents for P. aeruginosa and A. baumannii
Reimbursing for innovative antibiotics / Encouraging updates from the AMR conference
NIAID workshop: What is a robust PK-PD package?
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
How hard (and how) to Pull? Net value of Pull via a Transferrable Exclusivity Extension (TEE)
Global survey of novel antibiotic reimbursement models / PASTEUR Act introduced to US House
Non-traditional antibiotics: A pipeline review and an analysis of key development challenges
In Praise of Non-Inferiority
The hunt for oral antibiotics: Beyond Lipinski’s Rule of Five
FDA analysis of 40-years of antibacterial development: Dheman et al.
Impact of PASTEUR: 9.9m lives saved, ROI of 125:1
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet